STUDY EVALUATES PATIENT EXPERIENCES WITH BIOPSY-BASED GENOMIC TESTING
DURING ACTIVE SURVEILLANCE
from Urology Times - March 28, 2023
THE SAFETY AND ONCOLOGIC BENEFITS OF TRANSPERINEAL vs TRANSRECTAL MRI-GUIDED PROSTATE BIOPSY from Urology Times - March 27, 2023
3/11/23 …….BREAKING NEWS: FROM THE PROTECt TRIAL:
ANNOUNCED AT EAU23 3/11/2023
BREAKING NEWS out of Milan, Italy, which might be a whisper now, but is a boon for men and men's health worldwide.
LINKS TO ARTICLES ON PROTECT REPORT RELEASED THIS WEEKEND AT EAU23:
CNN: https://www.cnn.com/.../prostate-cancer.../index.html
NBC: https://www.nbcnews.com/.../study-finds-active-monitoring...
STUDY: https://www.nejm.org/doi/full/10.1056/NEJMoa2214122
SEE THE REMAINDER OF MY POST AT: https://www.asprostatecancer.blog/posts/protectstudy
3/11/23…… from MEDPAGE
DEATHS FROM PSA-DETECTED PROSTatE CANCER LOW AT 15 YEARS,
NO MATTER THE TREATMENT
3/2/23……Original Investigation Urology
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US
Matthew R. Cooperberg, MD, MPH1,2; William Meeks, MS3; Raymond Fang, MSC, MASC3; Franklin D. Gaylis, MD4; William J. Catalona, MD5; Danil V. Makarov, MD, MHS6
READ HERE:
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801916
